Page 5 - Cipla

Jigar S Patel of Anand Rathi recommends buying these three stocks today

After reaching a peak near the Rs 101-mark in September 2023, the IDFC First Bank stock experienced a substantial correction of 30 points, translating to a 29.34 per cent decline from its high.

Cipla to commence supplies to US from China plant later this year

Drug major Cipla expects to commence supplies to the US market from its China facility in the second half of the current fiscal after getting approval from the American health regulator, according to its MD and global CEO Umag Vohra. Addressing shareholders in the company's Annual Report for 2023-24, he noted that the company is working with the USFDA to resolve issues with its various domestic plants. "Although we saw challenging phases with USFDA audits, I am glad to report that our China facility cleared the USFDA audit and is expected to supply to the US by the second half of FY 2024- 25," Vohra said. Sharing updates about other plants, he noted that the facilities of Patalganga and Kurkumbh in India were also cleared with a VAI (voluntary action indicated). "Our Goa site was issued observations and our Indore plant is currently being remediated. Finding resolution for these regulatory issues continues to be our top priority," Vohra said. The company has worked extensively to

Cipla Q1 results: Net profit up 18% at Rs 1,177.64 cr, revenue rises 5.8%

Pharma major eyes new therapy areas to fuel future growth

In major boardroom reshuffle, Samina Hamied steps down from Cipla Board

The announcement comes amid reports that Cipla promoters are looking to sell their entire or partial shareholding in the company

Stocks to Watch, July 26: Tech M, Cipla, UBL, Power Grid, Sobha, Sanstar

In Asia, Japan's Nikkei traded up 0.27%, Hong Kong's Hang Seng rose 0.85%, and South Korea's Kospi increased 0.90%, while Shanghai Composite and Asia Dow traded flat on Friday morning.

Cipla Q1 Preview: Restructure in biz may dent sales; profits to rise 7%

Cipla is expected to see a decent June quarter with revenues estimated to increase in upper single digits on a year on year basis and net profits seeing a mid single digit growth

Orchid Pharma rises 4% on deal with Cipla to roll out new UTI drug in India

The rise came following Orchid Pharma's announcement of a collaboration with pharmaceutical giant Cipla to introduce the antibiotic Cefepime-Enmetazobactam in India

Orchid Pharma join hands with Cipla to launch new antibiotic in India

The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence

Stocks to watch on June 24: Sun Pharma, Cipla, Lupin, Vedanta, Tata Steel

Stocks to watch on June 24: USFDA has issued six observations for Cipla's Goa facility following an inspection from June 10 to June 21, 2024

Cipla to invest additional 3 mn euro in mRNA technology company Ethris

The aim is to accelerate Cipla's entry into the mRNA space and deliver innovative mRNA-based therapies, particularly targeting respiratory treatments, to patients in emerging markets

Stocks to Watch, June 12:L&T, Cipla, Patanjali Foods, TCS, TVS Supply Chain

Stocks to Watch on Wednesday, June 12: L&T expects private capex to pick up gradually post general elections in India in FY25.

Cipla, TVS Motor, Sun TV: Stock picks by Ajit Mishra of Religare Broking

Defensives are seeing strong activity, with pharma also performing well. Cipla, in particular, has achieved a fresh breakout from its consolidation range, reaching a new high

F&O Alert: These 3 Nifty stocks trade with high PCR; check key levels here

May F&O expiry strategy: In general, stocks with high Open Interest based Put Call Ratio (PCR) tend to trade with a positive bias or find strong support in case of dips.

Cipla rallies 4% on US FDA approval to market Lanreotide injection

The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.

Cipla receives USFDA approval to market Lanreotide injection in US

Drug major Cipla on Wednesday said it has received approval from the US health regulator to market a generic medication used to treat acromegaly and other conditions. The company has received the final approval from the US Food and Drug Administration (USFDA) to market Lanreotide injection in multiple strengths, the Mumbai-based drug maker said in a statement. The company's Lanreotide Injection is therapeutic equivalent generic version of Somatuline Depot Injection, it added. The drugmaker said its product is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumours. According to IQVIA (IMS Health), Somatuline Depot had sales of around USD 898 million in the US for the 12-month period ending March 2024.

Buy ideas for May 22: Britannia, Cipla; check target prices

Cipla was in a downtrend and corrected ~13 per cent in the recent fall. On the daily charts it formed an Inverted Head and Shoulders pattern which is a Trend reversal pattern

Cipla promoters sell 2.53% stake worth Rs 2,637 cr to fund philanthropy

ICICI Prudential MF, Aditya Birla Sun Life MF among top buyers

Cipla zooms 5% on 2.53% stake sale by Hamied family, Okasa Pharma

Promoters Shirin Hamied, Rumana Hamied, Samina Hamied and Okasa Pharma Private Limited have sold 2.53 per cent shares of Cipla for an undisclosed amount

Bharti Airtel, Cipla, Paytm, Colgate among seven stocks to track on May 15

At 6:55 AM, GIFT Nifty futures was trading 73 points higher at 22,382.50 levels compared to Nifty50 futures, indicating a positive start for the bourses

Promoter group to sell 2.53% stake worth $316 million in Cipla: Report

The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said